Drugs / MEDI0680
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02013804 | Dec 2013 → May 2017 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02271945 | Dec 2014 → May 2016 | aggressive B-cell non-Hodgkin lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT02118337 | May 2014 → Mar 2020 | clear cell renal carcinoma, high grade malignant neoplasm | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI0680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02013804 ↗ |
| Known as | AMP-514 | “MEDI0680 (AMP-514)” NCT02013804 ↗ |
| Action | Inhibit | “anti-programmed cell death-1 antibody MEDI0680” PMID 31439037 ↗ Aug 2019 |
| Modality | Monoclonal antibody | “Anti-PD-1 monoclonal antibody MEDI0680” PMID 31439037 ↗ Aug 2019 |
| Route | Intravenous | “MEDI0680 was administered intravenously once every 2 weeks (Q2W) or once every 3 weeks” PMID 31439037 ↗ Aug 2019 |